Ken Griffin Glaukos Corp Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$89.48 - $118.35 $2.05 Million - $2.71 Million	-22,900 Reduced 51.46%	21,600 $2.56 Million
Q1 2024 May 15, 2024	SELL	$76.4 - $96.33 $3.01 Million - $3.8 Million	-39,400 Reduced 46.96%	44,500 $4.2 Million
Q4 2023 Feb 14, 2024	BUY	$59.53 - $85.11 $3.09 Million - $4.42 Million	51,900 Added 162.19%	83,900 $6.67 Million
Q3 2023 Nov 14, 2023	BUY	$69.23 - $79.09 $27,692 - $31,636	400 Added 1.27%	32,000 $2.41 Million
Q2 2023 Aug 14, 2023	BUY	$45.44 - $71.21 $808,832 - $1.27 Million	17,800 Added 128.99%	31,600 $2.25 Million
Q1 2023 May 15, 2023	SELL	$43.88 - $52.48 $658,200 - $787,200	-15,000 Reduced 52.08%	13,800 $691,000
Q4 2022 Feb 14, 2023	BUY	$40.82 - $57.75 $346,970 - $490,875	8,500 Added 41.87%	28,800 $1.26 Million
Q3 2022 Nov 14, 2022	SELL	$46.84 - $58.49 $56,208 - $70,188	-1,200 Reduced 5.58%	20,300 $1.08 Million

303

47M

75.3K

157K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $6.19B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.